Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
33.36
+0.40 (1.21%)
Bozor ochiq: Aug 12, 2026, 12:27 PM EDT
32.96
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Stoke Therapeutics, Inc. oqsil ifodasini ko'tarish orqali og'ir genetik kasalliklarni davolashni ishlab chiqish bilan shug'ullanadi. Kompaniya oqsil darajasini tanlab tiklash uchun antisense oligonukleotidlarini (ASO) ishlab chiqishda o'zining xususiy Targeted Augmentation of Nuclear Gene Output (TANGO) yondashuvidan foydalanadi. Uning asosiy mahsulot nomzodlari qatoriga autosom-dominant optik atrofiya davolash uchun 1-bosqich klinik sinovlarida bo'lgan STK-002; va Dravet sindromini davolash uchun tadqiq qilinayotgan yangi dori bo'lgan Zorevunersen (STK-001) kiradi, bu 3-bosqich klinik sinovlarida baholanmoqda. Kompaniya, shuningdek, markaziy asab tizimi va ko'zning haploinsufficiency kasalliklari, shu jumladan turli maqsadlarga qaratilgan dasturlarni ishlab chiqadi. M Ehm, Dravet sindromini davolash uchun zorevunersen dori vositalarini ishlab chiqish va tijoratlashtirish uchun Biogen Inc. bilan; va Acadia Pharmaceuticals Inc. bilan genetik nevrologik rivojlanish kasalliklarini davolash uchun yangi RNKga asoslangan dori vositalarini kashf qilish, ishlab chiqish va tijoratlashtirish bo'yicha litsenziyasi va hamkorligi mavjud. Kompaniya ilgari ASOthera Pharmaceuticals, Inc. nomi bilan tanilgan va 2016 yil may oyida Stoke Therapeutics, Inc. nomini o'zgartirgan. Stoke Therapeutics, Inc. 2014 yilda ro'yxatga olingan va shtab-kvartirasi Bedford, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Adrian R. Krainer Ph.D. | Co-Founder & Independent Director |
| Dr. Edward M. Kaye M.D., Ph.D. | Advisor & Director |
| Dr. Thomas McCauley Ph.D. | Chief Scientific Officer |
| Mr. Ian F. Smith A.C.A., C.P.A. | CEO & Director |
| Mr. Jason Hoitt | Chief Patient Officer |
| Mr. Jonathan Allan J.D. | Corporate Secretary, Compliance Officer & General Counsel |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-03 | S-8 | d63235ds8.htm |
| 2026-08-03 | 8-K | d135735d8k.htm |
| 2026-06-30 | 8-K | d924679d8k.htm |
| 2026-06-04 | 8-K | d15052d8k.htm |
| 2026-05-07 | 8-K | stok-20260507.htm |
| 2026-05-07 | 10-Q | stok-20260331.htm |
| 2026-04-22 | DEFA14A | d79682ddefa14a.htm |
| 2026-04-22 | DEF 14A | d941184ddef14a.htm |
| 2026-04-22 | ARS | d16721dars.pdf |
| 2026-04-07 | 8-K | d63742d8k.htm |
| Mr. Thomas Edward Leggett | Chief Financial Officer |
| Ms. Isabel Aznarez Ph.D. | Co-Founder & CTO |
| Ms. Sara Den Besten | Chief People Officer |
| Susan Willson | Vice President of Corporate Communications |